BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Patients with classical HL CD30+ confirmed histologically (either at the time of diagnosis / at the time of first relapse) will be included in the trial

• Male or female patients 18 to 65 years of age
• Voluntary written informed consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
• Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse
• Male patients, even if surgically sterilized, (i.e., status post-vasectomy) agree to practice effective barrier contraception during the entire study period and through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse
• ECOG 0 to 2
• Measurable disease at time of enrolment (lymphadenopathy/ extranodal mass of at least 1.5 cm)
• No evidence of neuropathy grade ≥2
• Clinical laboratory values as specified in the protocol below within 7 days before the first dose of study drug

Exclusion Criteria:

• Lymphocyte predominant nodular Hodgkin's lymphoma
• Prior treatment with brentuximab vedotin
• Female patient who are both lactating and breast-feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug
• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol.
• Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
• Symptomatic neurologic disease compromising normal activities of daily living or requiring medic
• Any sensory or motor peripheral neuropathy greater than or equal to Grade 2
• Known history of any of the following cardiovascular conditions defined in the protocol
• Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first study drug dose
• Patients that have not completed any prior treatment chemotherapy and/or other investigational agents within at least 5 half-lives (or 28 days if the half-lives are unknown) of last dose of that prior treatment
• Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin.
• Known human immunodeficiency virus (HIV) positive
• Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
• Focal radiation therapy within 30 days prior to study recruitment
• Major surgery within 28 days prior to randomization
• Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease.
• Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.